ICU Investors Have Opportunity to Lead SeaStar Medical Holding Corporation Securities Fraud Lawsuit with the Schall Law Firm
17 juil. 2024 11h30 HE
|
Schall Law
ICU Investors Have Opportunity to Lead SeaStar Medical Holding Corporation Securities Fraud Lawsuit with the Schall Law Firm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SeaStar Medical Holding Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – ICU
11 juil. 2024 17h07 HE
|
The Rosen Law Firm PA
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of...
ICU Investors Have Opportunity to Lead SeaStar Medical Holding Corporation Securities Fraud Lawsuit with the Schall Law Firm
10 juil. 2024 12h00 HE
|
Schall Law
ICU Investors Have Opportunity to Lead SeaStar Medical Holding Corporation Securities Fraud Lawsuit with the Schall Law Firm
SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
11 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
11 mars 2024 16h05 HE
|
SeaStar Medical Holding Corporation
March 13 webcast showcasing Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024...
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
15 févr. 2023 16h01 HE
|
SeaStar Medical Holding Corporation
The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD’s ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation ...
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
14 févr. 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Feb. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
09 févr. 2023 08h19 HE
|
SeaStar Medical Holding Corporation
Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
31 janv. 2023 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
09 janv. 2023 08h25 HE
|
SeaStar Medical Holding Corporation
Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) --...